HIGHLIGHTS
SUMMARY
More generally, in patients suffering from ILDs (including RA-ILD), a significant proportion is exhibiting a fibrotic progression despite appropriate treatment and regardless of the underlying ILD, defined as progressive fibrosing interstitial lung disease (PF-ILD). In 2019, the INBUILD trial used arbitrary criteria for progression of ILD within 24 months before screening, despite standard treatment with an agent other than nintedanib or pirfenidone: Among a global RA patients` cohort, this retrospective study investigates the frequency and compares the characteristics and mortality rates of RA-ILD (vs. other RA) patients and PF-ILD (vs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.